Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.

J Neurol · 2026 · PMC13102939 · PMID 42018029

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although improvements in the brainstem and bladder/bowel did not reach statistical significance, the trend was equally favourable for alemtuzumab According to the MSFC scale, worsening ≥ 15% at 24 months was lower with alemtuzumab than with interferon.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.